COEP
Coeptis Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About COEP
Coeptis Therapeutics Holdings, Inc.
A biopharmaceutical company that developing innovative cell therapy platforms for cancer
Life Science Tools and Services
Invalid Date
12/17/2020
NASDAQ Stock Exchange
7
12-31
Common stock
105 Bradford Rd, Suite 420, Wexford, Pennsylvania, 15090
--
Coeptis Therapeutics Holdings, Inc., originally incorporated in Colorado in 1996 as Nelx Marketing Inc., later changed its name to Mind 2 Market, Inc. (1996) and then to Health Partnership, Inc. (2005), It was then renamed Naerodynamics, Inc. (2008). In January 2020, Coeptis moved to Delaware and changed its then corporate name to NDYN Merger Corp. In February 2020, NDYN Merger Corp. promulgated a holding company reorganization under Section 251 (g) of the DGCL and changed the company name to Vinings Holdings, Inc. Effective July 12, 2021, the company name will be changed to "Coeptis Therapeutics, Inc." Coeptis' current business model is designed around further developing its existing product portfolio. Coeptis is constantly exploring partnership opportunities with companies at different stages of development with new therapies or with technologies that improve the way they deliver medicines to patients. Coeptis seeks optimal strategic relationships that can include in-licensing agreements, out-of-licensing agreements, co-development arrangements, and other strategic partnerships in new and exciting therapeutic areas such as autoimmune diseases and oncology.
Company Financials
EPS
COEP has released its 2023 Q3 earnings. EPS was reported at -0.23, versus the expected -0.01, missing expectations. The chart below visualizes how COEP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
COEP has released its 2025 Q1 earnings report, with revenue of 62.87K, reflecting a YoY change of NaN%, and net profit of -3.42M, showing a YoY change of -13.98%. The Sankey diagram below clearly presents COEP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
